1. Home
  2. VRME vs CANF Comparison

VRME vs CANF Comparison

Compare VRME & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRME
  • CANF
  • Stock Information
  • Founded
  • VRME 1999
  • CANF 1994
  • Country
  • VRME United States
  • CANF Israel
  • Employees
  • VRME N/A
  • CANF N/A
  • Industry
  • VRME EDP Services
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRME Technology
  • CANF Health Care
  • Exchange
  • VRME Nasdaq
  • CANF Nasdaq
  • Market Cap
  • VRME 14.5M
  • CANF 14.4M
  • IPO Year
  • VRME N/A
  • CANF N/A
  • Fundamental
  • Price
  • VRME $1.32
  • CANF $2.36
  • Analyst Decision
  • VRME Buy
  • CANF Strong Buy
  • Analyst Count
  • VRME 1
  • CANF 2
  • Target Price
  • VRME $1.50
  • CANF $14.00
  • AVG Volume (30 Days)
  • VRME 15.0K
  • CANF 114.9K
  • Earning Date
  • VRME 11-06-2024
  • CANF 11-15-2024
  • Dividend Yield
  • VRME N/A
  • CANF N/A
  • EPS Growth
  • VRME N/A
  • CANF N/A
  • EPS
  • VRME N/A
  • CANF N/A
  • Revenue
  • VRME $25,428,000.00
  • CANF $667,000.00
  • Revenue This Year
  • VRME $1.14
  • CANF $356.93
  • Revenue Next Year
  • VRME $10.56
  • CANF N/A
  • P/E Ratio
  • VRME N/A
  • CANF N/A
  • Revenue Growth
  • VRME N/A
  • CANF N/A
  • 52 Week Low
  • VRME $0.85
  • CANF $1.81
  • 52 Week High
  • VRME $2.45
  • CANF $4.69
  • Technical
  • Relative Strength Index (RSI)
  • VRME 48.69
  • CANF 60.97
  • Support Level
  • VRME $1.28
  • CANF $1.87
  • Resistance Level
  • VRME $1.43
  • CANF $2.04
  • Average True Range (ATR)
  • VRME 0.11
  • CANF 0.17
  • MACD
  • VRME -0.01
  • CANF 0.04
  • Stochastic Oscillator
  • VRME 32.04
  • CANF 72.06

About VRME VerifyMe Inc.

VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: